Alector | Therapies to Remember
Slide background

We are a biotech company dedicated to the discovery and development of novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically similar disorders.

Slide background

"Excellence is never an accident. It is always the result of high intention, sincere effort, and intelligent execution; it represents the wise choice of many alternatives – choice, not chance, determines your destiny.”
- Aristotle

Our Mission

To Discover and Develop Novel, Disease Modifying Therapies for Dementia and Mechanistically Similar Disorders

About Alector

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically similar disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets.  This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months.  Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.


Thought leaders in biotechnology, neuroscience, and antibody drug discovery

  • All
  • Board
  • Founders
  • Operations
  • Scientists

Co-Founder, President, CSO, Board Member, Chairman of Scientific Advisory Board - Rinat Neuroscience Corp. (acquired by Pfizer in 2006)

Co-Founder, Board Member - Annexon Inc.

Member of Scientific Advisory Board - Simons Foundation Autism Research Initiative

Member of Scientific Advisory Board - Myelin Repair Foundation

Former Member of Scientific Advisory Board for Neuroscience - UCB Pharma

Executive Scientist, Member of the Research Review Committee - Genentech Inc.

Arnon Rosenthal, PhD
Co-Founder, CEO, President

Co-Founder - ShanaRX Pharmaceuticals

Postdoctoral Researcher - Genentech Inc.

Tenured Associate Professor - Taub Institute at Columbia University, Departments of Pathology and Neurology

Diplomate in Neurology - American Board of Psychiatry and Neurology

Asa Abeliovich, MD PhD
Co-Founder, SAB Member

Co-Founder, CEO - Adimab LLC

Co-Founder, Chairman of the Board - Arsanis Inc.

Co-Founder, Chairman of the Board - Avitide Inc.

Co-Founder, CSO - GlycoFi (acquired by Merck in 2006)

Professor of Bioengineering - Dartmouth College

Venture Partner - SV Life Sciences

Tillman Gerngross, PhD
Co-Founder, Chairman of the Board

Scientist - Sutro Biopharma

Postdoctoral Research Fellow and Research Associate - Memorial Sloan-Kettering Cancer Center, Department of Immunology

Doctoral Research Scientist - European Institute of Oncology (Italy) and University of Cambridge (UK)

Francesca Avogadri-Connors, PhD
Lead Scientist - Neuroimmunology; Cell & In Vivo Biology

Founding Partner, Co-Head of Global Private Equity - OrbiMed

Senior Biotechnology Analyst - Mehta and Isaly

Fellow - The Rockefeller University

Carl Gordon, PhD CFA
Board Member, Investor

Director of Manager Research - North Creek Advisors

Senior Associate - The Parthenon Group

Analyst - Dean & Company

Kelly Hackett
General Manager

Lab Manager - Dartmouth College

10+ years experience working in academic and industrial labs

Experience in GMP environments

Helped set up 3 new labs from start to finish

Heather Jewell
Lab Manager

MS, Biomedical Science, Concentration in Biotechnology - San Francisco State University

BS, Biochemistry and Molecular Biology - University of California, Davis

Helen Lam
Research Associate - Cell Biology

Co-Founder, General Partner - Polaris Partners

Co-Founder - Inspire Pharmaceuticals, AIR, MicroCHIPS

Chairman of the Board - Thayer School of Engineering, Dartmouth College

Board Member - MIT’s The David H. Koch Institute for Integrative Cancer Research

Board Member - The Arthur Rock Center for Entrepreneurship at HBS

2005 Recipient - Albert Einstein Award for Outstanding Achievement in Life Sciences

Terry McGuire
Board Member, Investor

Postdoctoral Research Fellow - Gladstone Institute of Virology and Immunology

Doctoral Research - University of California Berkeley, Program in Cell and Molecular Biology

Research Technician - University of Utah, Department of Human Genetics

Kate Monroe, PhD
Lead Scientist - Neuroimmunology & Cell Biology

Graduate Research Assistant - University of North Carolina

Graduate Research Assistant - East Carolina University

PhD Chemistry - University of North Carolina, Chapel Hill

William Monteith, PhD
Associate Scientist - Protein Biochemistry

Postdoctoral Fellow - The Rockefeller University

Graduate Research Assistant - Northwestern University

Andrew Pincetic, PhD
Lead Scientist - Protein Biochemistry & Engineering

Postdoctoral Research Fellow and Research Associate - Stanford University, Department of Neurobiology

Postdoctoral Research Fellow - Rockefeller University

Doctoral Research Scientist - Rockefeller University and University of Hohenheim, Germany

Tina Schwabe, PhD
Lead Scientist - Neurogenetic & Cell Biology

Co-Founder, Director of Finance & Operations - Avitide Inc.

Director of Finance & Operations - Arsanis Inc.

Bain Capital Ventures

McKinsey & Company

Founder - Bedrock Ventures

Jonathan Sheller
Director of Finance & Operations

Research Fellow - National Institute of Health, Laboratory of Molecular Immunology

Postdoctoral Research Fellow - Washington University, Department of Pathology

Doctoral Research Scientist - Washington University and La Sapienza University of Rome, Department of Experimental Medicine

Ilaria Tassi, PhD
Lead Scientist - Neuroimmunology; Cell Signaling & In Vivo Biology

Our Investors

Alector is backed by leading venture capital firms



under management



OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector, with over $8 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies. OrbiMed’s team of more than 80 employees manages a series of private equity funds, public equity funds, royalty/debt funds and other investment vehicles. OrbiMed maintains its headquarters in New York City, with additional offices in San Francisco, Shanghai, Mumbai and Herzliya.



under management



Polaris Venture Partners is a partnership of experienced private equity investors, operating executives and entrepreneurs. The firm’s mission is to identify, invest in and partner with seed, early stage, and middle market businesses with exceptional promise and help them grow into market-leading companies. The firm has over $3.5 billion under management, more than 20 investment professionals, and current investments in more than 100 companies.

Neurodegenerative Diseases



Americans living with




leading cause of death

in the US



direct cost of caring for

Alzheimer’s patients to US

Alzheimer’s disease is the most common form of dementia, affecting over 5 million people in the US alone. It is characterized by gradual mental deterioration, loss of memory, and eventually death (it is the 6th-leading cause of death in the US). AD is a high-profile disease with diagnosis incidence rates expected to rise rapidly due to demographic trends. 11% of those over 65 have been diagnosed with Alzheimer’s. There are currently no methods to prevent, cure, or meaningfully slow its progression. In 2011, the Alzheimer’s disease drug market was a $5.8B. It is expected to grow to $14.5B by 2020 (excluding novel treatments and all other forms of dementia). The cost of care for Alzheimer’s is estimated to grow from $203B in 2013, to $1.2T in 2050. Other forms of dementia including frontotemporal dementia, are less common, with 100K-200K patients in the US, and are thus considered orphan diseases. No therapeutics have been shown to alter the inexorable courses of these disorders. Alector’s therapeutic targets are relevant to certain non-CNS disorders such as atherosclerosis and arthritis, and these common disorders thus constitute secondary indications for Alector. The market sizes of these secondary indications exceed those for Alector’s primary disease indications.

What Others Are Saying About Alzheimer’s

It’s an epidemic, it’s on the rise, and currently there is no way to delay it, prevent it or cure it.

– Maria Carrillo, PhD (Alzheimer’s Association)

If dementia care were a country, it would be the world’s 21st largest economy, ranking between Poland and Saudi Arabia.

– Alzheimer’s Association

We’ve had great success in this country when we’ve decided to focus on a condition. We’ve done it with good research in heart disease, cancer and HIV, but we are in our infancy when it comes to Alzheimer’s research.

– Jennifer Weuve, MPH ScD (Assistant Professor, Rush Medical College)

Recent News

  • Top 30 Life Science Startups To Watch In The U.S.

    BioSpace is delighted to present its NextGen Bio “Class of 2015.” This list contains 30 life science companies that were launched no earlier than in 2011 and are headquartered in the United States. Once the companies were sorted into that group, they were then weighted......

    23 Oct 2014
  • New Janssen Labs Incubator Could Bring Up to 50 Companies to South SF

    Tiny biotech startups will have a new place to germinate in the San Francisco Bay Area. Healthcare giant Johnson & Johnson’s Janssen Labs division is opening a new 30,000 square foot incubator in the biotech-rich suburb of South San Francisco. The flexible space, complete with......

    14 May 2014
  • Johnson & Johnson, Alector team up on Alzheimer’s therapies

    In a novel partnership, Janssen Pharmaceuticals said Monday it will fund San Francisco biotech startup Alector’s efforts to develop new therapies for Alzheimer’s disease. The research agreement between Alector and Janssen, the pharmaceutical arm of Johnson & Johnson, reflects a growing relationship between young biotech......

    11 Mar 2014